Supplementary Table 1 Clinical and Tumor Characteristics of Evaluated Cohorts and Entire

Jogl et al

Supplementary table 1 Clinical and Tumor characteristics of evaluated cohorts and entire cohorts stratified according to RBM3 protein expression

Cohort I (n = 516) / Cohort II (n = 500)
RBM3 status known / RBM3 status unknown / p-value / RBM3 status known / RBM3 status unknown / p-value
Category / n=241(%) / n=271(%) / n=311(%) / n=253(%)
Age (years)
median (range) / 65(27-96) / 64(28-92) / 0.91 / 44(27-57) / 45(25-55) / 0.81
Randomization
Tamoxifen / 148 (48) / 128 (51) / 0.48
Control / 163 (52) / 125 (49)
Tumour size
>=20mm / 153 (63) / 168 (62) / 0.73 / 107 (34) / 102 (40) / 0.16
>20mm / 88 (37) / 103 (38) / 203 (66) / 151 (60)
missing / 0 / 0 / 1 / 0
Grade
I / 52 (22) / 75 (27) / 0.43 / 30 (10) / 28 (11) / 0.07
II / 109 (45) / 104 (39) / 127 (41) / 95 (38)
III / 79 (33) / 91(34) / 148 (48) / 26 (10)
missing / 1 / 1 / 6 (2) / 44 (17)
Nodal status
Negative / 138 (57) / 153 (57) / 0.87 / 85 (27) / 74 (29) / 0.61
Positive / 80 (33) / 86 (32) / 225 (72) / 128 (51)
missing / 24 (10) / 32 (12) / 1 / 1
ER status
Negative / 25 (10) / 47 (17) / 0.007 / 104 (33) / 47 (19) / 0.07
Positive / 212 (87) / 195 (71) / 196 (63) / 129 (51)
missing / 4 (3) / 29 (12) / 11 (4) / 77 (30)
PR status
Negative / 60 (25) / 81 (30) / 0.008 / 101 (32) / 46 (18) / 0.08
Positive / 130 (54) / 99 (37) / 189 (60) / 124 (49)
missing / 51 (21) / 91 (33) / 21 (7) / 73 (29)
Her2
0 / 90 (37) / 55 (20) / 0.19 / 170 (55) / 81 (32) / 0.30
1+ / 46 (19) / 53 (20) / 44 (14) / 31 (12)
2+ / 13 (5) / 14 (5) / 21 (7) / 17 (7)
3+ / 14 (5) / 10 (4) / 42 (14) / 23 (9)
missing / 109 (45) / 108 (40) / 34 (11) / 101 (40)
Ki67
0-10% / 93 (39) / 89 (33) / 0.42 / 115 (37) / 80 (32) / 0.09
11-25% / 81(33) / 78 (29) / 86 (28) / 32 (13)
>25% / 61(25) / 71 (26) / 79 (25) / 39 (15)
missing / 6 (3) / 33 (12) / 31 (10) / 102 (40)

Abbreviations: ER =estrogen receptor; PR=progesterone receptor